After more than 10 years of use, rituximab has proven to be remarkably safe. However,
accumulated evidence now suggests that under some circumstances it may significantly
increase the risk of infections. This risk is difficult to quantify because of confounding factors
(namely, concomitant use of immunosuppressive or chemotherapeutic agents and
underlying conditions), as well as under-reporting. Increased number of infections has been
documented in patients treated with maintenance rituximab for low-grade lymphoma and in …